Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method
A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH) 2 ), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.
1. A delivery composition, comprising a treatment agent microencapsulated in degradable microcapsules that are suspended in a degradable thermo-responsive hydrogel, wherein the degradable microcapsules comprise magnesium hydroxide (Mg(OH) 2 ), bovine serum albumin (BSA) and sucrose, wherein the hydrogel is thermo-responsive at a physiological temperature of about 32° C. to about 37° C., wherein the treatment agent is selected from an anti-VEGF agent, an anti-PDGF agent, cells, delivery cells, an antibiotic, a corticosteroid, enzymes, peptides, nucleic acids, or combinations thereof.
2. The composition of claim 1 , wherein the microcapsules comprise:
0.001% to 20% w/v BSA; and
0.001% to 9% w/v Mg(OH) 2 .
3. The composition of claim 1 , wherein the microcapsules further comprise polyethylene glycol (PEG).
4. The composition of claim 3 , wherein the microcapsules comprise:
0.001% to 20% w/v BSA;
0.001% to 9% w/v Mg(OH) 2 ;
0.001% to 20% w/v PEG; and
0.001% to 10% w/v sucrose.
5. The composition of claim 3 , wherein the microcapsules comprise:
about 10-14% w/v % BSA;
about 2-4% w/v Mg(OH) 2 ;
about 8-12% w/v PEG; and
about 1.5-3.5% w/v sucrose.
6. The composition of claim 1 , wherein the microcapsules further comprise poly(lactic-co-glycolic acid), poly(lactic acid), polysaccharide chitin, alginate, or combinations or block copolymers thereof.
7. The composition of claim 6 , wherein the microcapsules further comprise polyethylene glycol (PEG).
8. The composition of claim 1 , further comprising a non-encapsulated treatment agent dispersed within the hydrogel.
9. The composition of claim 1 , further comprising microcapsules having at least two release rates.
10. The composition of claim 1 , wherein the hydrogel comprises poly(N-isopropylacrylamide), poly(lactic acid), polysaccharide chitin, alginate, diacrylate, or combinations or block copolymers thereof.
11. A delivery composition, comprising a treatment agent microencapsulated in degradable microcapsules suspended in a degradable thermo-responsive hydrogel, wherein the degradable microcapsules comprise magnesium hydroxide (Mg(OH) 2 ), bovine serum albumin (BSA), and sucrose, wherein the hydrogel is thermo-responsive at a physiological temperature of about 32° C. to about 37° C. to provide a liquid-like state at room temperature and more solid state at body temperature and wherein the treatment agent is selected from an anti-VEGF agent, an anti-PDGF agent, cells, delivery cells, an antibiotic, a corticosteroid, enzymes, peptides, nucleic acids, or combinations thereof.
12. The composition of claim 11 , wherein the microcapsules further comprise:
poly(lactic-co-glycolic acid), poly(lactic acid), polysaccharide chitin, alginate, or combinations or block copolymers thereof;
0.001% to 20% w/v BSA;
0.001% to 9% w/v Mg(OH) 2 ;
0.001% to 20% w/v PEG; and
0.001% to 10% w/v sucrose.
13. The composition of claim 11 , wherein the degradable microcapsules further comprise polyethylene glycol (PEG).
14. A method of delivering the composition of claim 1 to an eye, the method comprising:
applying to or into an eye of a mammal the composition in a first physicochemical state; and
the composition changing to a second physicochemical state upon administration, wherein the second physicochemical state is more solid than the first physicochemical state, wherein the degradable microcapsules release the microencapsulated treatment agent over time after applying.
15. The method of claim 14 , wherein the microcapsules comprise:
0.001% to 20% w/v BSA; and
0.001% to 9% w/v Mg(OH) 2 .
16. The method of claim 14 , wherein the microcapsules comprise:
0.001% to 20% w/v BSA;
0.001% to 9% w/v Mg(OH) 2 ;
0.001% to 20% w/v PEG; and
0.001% to 10% w/v sucrose.
17. The method of claim 14 , wherein the microcapsules further comprise poly(lactic-co-glycolic acid), poly(lactic acid), polysaccharide chitin, alginate, diacrylate or combinations or block copolymers thereof.
18. The method of claim 14 , wherein the composition in the second physicochemical state is degradable to release the microencapsulated treatment agent and further comprising controlling the degradation by at least one of: selection of a type and/or amount of crosslinking to control the release of the microencapsulated treatment agent, or selection of organic solvent used in microencapsulation of the treatment agent.
19. The method of claim 14 , further comprising applying the composition in a first physicochemical state by intravitreal injection, by periocular or transcleral injection, by topical application, by intracameral application, by suprachoroidal application, within ocular implants, or combinations thereof.
20. The method of claim 14 , wherein the degradable microcapsules release the microencapsulated treatment agent over six months after applying.